The Jump Shot
Forbes Indonesia|October 2021
Under Jahja Tear Tjahjana’s leadership, Oneject Indonesia is enhancing its global and domestic auto-disable syringes’ market.
Apriza Pinandita

The race to vaccinate the world’s population against COVID-19 reached a new milestone with the World Health Organization (WHO) reporting that at least 5.9 billion vaccine doses have been administered globally as of September 2021. In Indonesia, latest figures show that 140 million vaccine doses have been administered and 50 million citizens are now fully vaccinated, around 18% of the total population.

This commitment to vaccinating millions of people during the pandemic has fueled the demand for medical devices, including syringes. Oneject Indonesia, like other manufacturers of syringes worldwide, is aiming to quadruple its production capacity in order to meet market demand.

Oneject Indonesia is a pioneer in the local production of single use auto-disable syringes (AD syringes), seeking to contribute to a reduction in the use of conventional syringes which carry the risk of being re-used and thereby contributing to the spread of diseases. Although the WHO has recommended the use of AD syringes since last year, they are still not widely used by healthcare stakeholders globally due to a limited supply and a higher price compared to standard syringes. Locally, AD syringes sell for around Rp1,200 per unit 10% higher compared to standard syringes.

Jahja Tear Tjahjana, CEO of Oneject Indonesia, says the WHO guidance aims to modernize traditional injection practices. “However, because this would be a drastic change, immunization programs are being focused on for the time being. AD syringes presently account for less than 10% of the global market for injection devices, one estimated to be worth $12.33 billion in 2020. It accounts for approximately 10% to 15% of total syringe usage globally,” Jahja says.

Continue reading your story on the app

Continue reading your story in the magazine

MORE STORIES FROM FORBES INDONESIAView All

THE CROESUS OF CRYPTO

FTX COFOUNDER SAM BANKMAN-FRIED BUILT A $22.5 BILLION FORTUNE BEFORE HIS 30TH BIRTHDAY BY PROFITING OFF THE CRYPTOCURRENCY FRENZY—BUT HE’S NOT A TRUE BELIEVER. HE JUST WANTS HIS WEALTH TO SURVIVE LONG ENOUGH TO GIVE IT ALL AWAY.

10+ mins read
Forbes Indonesia
November 2021

The Cost of Looking Good

The fashion industry is at the tipping point of turning sustainable.

5 mins read
Forbes Indonesia
November 2021

Resilient Sectors in Greater Jakarta Amid the Pandemic

The pandemic has resulted in a challenging period for much of the Greater Jakarta real estate market.

2 mins read
Forbes Indonesia
November 2021

Sweet Dream

On 17 August 2021, PTPN, the national state-owned plantation company, with government support, officially established PT Sinergi Gula Nusantara (SugarCo) by bringing together 35 sugar mills owned by seven of its members under a single entity subsidiary.

4 mins read
Forbes Indonesia
November 2021

To the Moon

Tokocrypto takes early steps to integrate blockchain and crypto technology into Indonesian society

4 mins read
Forbes Indonesia
November 2021

ROADS TO SUCCESS

JUSUF HAMKA ASPIRES TO TURN CITRA MARGA NUSAPHALA PERSADA INTO A RP100 TRILLION COMPANY, IN TERMS OF ASSETS.

6 mins read
Forbes Indonesia
November 2021

Reshaping Business

At the height of COVID-19 pandemic, Hero Supermarket executes a major decision to divest Giant. Now, it is recalibrating business to regain profitability.

5 mins read
Forbes Indonesia
November 2021

Humility Matters

TAUFIK DARUSMAN IS ONE OF INDONESIA’S MOST EXPERIENCED JOURNALISTS. HE HAS HELD CHIEF EDITOR ROLES AT BUSINESS WEEK INDONESIA AND INVESTOR MAGAZINES, AND THE INDONESIAN OBSERVER NEWSPAPER.

2 mins read
Forbes Indonesia
November 2021

Opportunity in The Rise of Palm Oil Prices

What would you do if you had $5 billion in cash?

4 mins read
Forbes Indonesia
November 2021

Bridging the Gap

Komunal provides a platform that connects depositors to rural banks that rely on brick-and-mortar branches.

4 mins read
Forbes Indonesia
November 2021
RELATED STORIES

A Crash Course in Omicronomics

Sussing out the impact of the new coronavirus variant on growth and inflation

4 mins read
Bloomberg Businessweek
December 06, 2021

OMICRON UNRAVELS TRAVEL INDUSTRY'S PLANS FOR A COMEBACK

Tourism businesses that were just finding their footing after nearly two years of devastation wrought by the COVID-19 pandemic are being rattled again as countries throw up new barriers to travel in an effort to contain the omicron variant.

5 mins read
AppleMagazine
December 03, 2021

PRESCRIPTION FOR 2022 - These Health Care Stocks Should Thrive

Pharmaceutical and health sciences firms are riding powerful demographic trends amid a golden age of innovation.

7 mins read
Kiplinger's Personal Finance
January 2022

Strongmen? Us?

Don’t let their confidence fool you: Xi, Putin, and other authoritarians are increasingly vulnerable at home

6 mins read
Bloomberg Businessweek
November 22 - 29, 2021

We're Not There Yet

To end the pandemic, we need more vaccinations—not just new pills

4 mins read
Bloomberg Businessweek
November 15, 2021

Unvaccinated? Time to Make an End-of-Life Plan

A good idea for anyone, advanced directives are especially important if you’re willing to risk a potentially fatal illness

4 mins read
Newsweek
November 05, 2021

Worth a Shot

Doctors and health experts strongly back COVID vaccination for kids. PARENTS aren’t so sure

10+ mins read
Newsweek
November 05, 2021

Sharing a Common Goal

Why Puerto Rico is the most vaccinated place in America

4 mins read
Newsweek Europe
November 12, 2021

Self-Care 101

How to create a nourishing self-care routine that can help you feel calmer, more centered, and better able to face the challenges of the world around you.

6 mins read
Better Nutrition
November 2021

The LONG Journey BACK

DAYS’s Suzanne Rogers shares the harrowing details of the medical scare that kept her out of Salem for six months.

9 mins read
Soap Opera Digest
October 11, 2021